Alamar Biosciences, Alzheimer’s Disease Data Initiative, and Gates Ventures launched a global partnership to generate expansive proteomic datasets aimed at accelerating biomarker discovery in Alzheimer's disease. Meanwhile, Ionis Pharmaceuticals initiated a pivotal Phase 3 study of ION582 for Angelman syndrome, targeting rare neurodevelopmental disorders. In oncology, Saga Diagnostics introduced a tumor-informed breast cancer MRD test for early detection and treatment monitoring. These advances highlight strategies integrating diagnostics and therapeutics for improved patient outcomes in complex diseases.